Publications Supported by the DOVE Project

Printer-friendly versionPrinter-friendly version
  1. Abubakar A, Azman AS, Rumunu J, et al. The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan. PLoS Med 2015; 12(11): e1001901.

  2. Aibana O, Franke MF, Teng JE, Hilaire J, Raymond M, Ivers LC. Cholera vaccination campaign contributes to improved knowledge regarding cholera and improved practice relevant to waterborne disease in rural Haiti. PLoS Negl Trop Dis 2013; 7(11): e2576.

  3. Ali M, Debes AK, Luquero FJ, et al. Potential for Controlling Cholera Using a Ring Vaccination Strategy: Re-analysis of Data from a Cluster-Randomized Clinical Trial. PLoS Med 2016; 13(9): e1002120.

  4. Ali, M., Gupta, S., Arora, N., Khasnobis, P., et al. Identification of burden hotspots and risk factors for cholera in India: An observational studyPLoS One 2017; 12(8): e0183100.

  5. Ali, M., Kim, P., Zaman, K., Clemens, J. Herd protection of unvaccinated adults by oral cholera vaccines in rural Bangladesh. International Health 2018;  ihy085.

  6. Ali, M., Nelson, A., Luquero, F., Azman, A., et al. Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort studyThe Lancet Infectious Diseases 2017; 17(5): 538-544.

  7. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis 2015; 9(6): e0003832.

  8. Ali M, You YA, Kanungo S, et al. Assessing different measures of population-level vaccine protection using a case-control study. Vaccine 2015; 33(48): 6878-83.

  9. Ali M, You YA, Sur D, et al. Validity of the estimates of oral cholera vaccine effectiveness derived from the test-negative design. Vaccine 2016; 34(4): 479-85.

  10. Anh DD, Lopez AL, Tran HT, et al. Oral cholera vaccine development and use in Vietnam. PLoS Med 2014; 11(9): e1001712.

  11. Azman AS, Ivers LC, Legros D, Luquero FJ, Mintz ED. Safe water, sanitation, hygiene, and a cholera vaccine. The Lancet 2016; 387(10013): 28.

  12. Azman AS, Legros D, Lessler J, Luquero FJ, Moore SM. Outbreaks of cholera in the time of Ebola: pre-emptive action needed. The Lancet 2015; 385(9971): 851.

  13. Azman AS, Luquero FJ, Ciglenecki I, Grais RF, Sack DA, Lessler J. The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Med 2015; 12(8): e1001867.

  14. Azman AS, Parker LA, Rumunu J, et al. Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. The Lancet Glob Health 2016; 4(11): e856-e63.

  15. Azman AS, Rumunu J, Abubakar A, et al. Population-Level Effect of Cholera Vaccine on Displaced Populations, South Sudan, 2014. Emerg Infect Dis 2016; 22(6): 1067-70.

  16. Bi, Q., Ferreras, E., Pezzoli, L., Legros, D., Ivers, L. C., Date, K., et al. Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases 2017; 17(10): 1080-1088.

  17. Bwire, Godfrey, Ali, M, Sack DA, et al. Identifying cholera" hotspots" in Uganda: An analysis of cholera surveillance data from 2011 to 2016PLoS neglected tropical diseases 11.12 (2017): e0006118.

  18. Chakraborty S, Alam M, Scobie HM, Sack DA. Adaptation of a simple dipstick test for detection of Vibrio cholerae O1 and O139 in environmental water. Frontiers in microbiology 2013; 4: 320.

  19. Ciglenecki, Isa, Azman AS, Rumunu, J, et al. Vaccination against cholera in Juba - Authors' reply. The Lancet Infectious Diseases 2017; 17(5): 480-481.

  20. Debes AK, Ali M, Azman AS, Yunus M, Sack DA. Cholera cases cluster in time and space in Matlab, Bangladesh: implications for targeted preventive interventions. International Journal of Epidemiology 2016.

  21. Debes AK, Ateudjieu J, Guenou E, et al. Clinical and Environmental Surveillance for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year Surveillance in the Far North Region of Cameroon. Am J Trop Med Hyg 2016.

  22. Debes AK, Ateudjieu J, Guenou E, et al. Evaluation in Cameroon of a Novel, Simplified Methodology to Assist Molecular Microbiological Analysis of V. cholerae in Resource-Limited Settings. PLoS Negl Trop Dis 2016; 10(1): e0004307.

  23. Deen J, Ali M, Sack D. Methods to assess the impact of mass oral cholera vaccination campaigns under real field conditions. PLoS One 2014; 9(2): e88139.

  24. Deen J, von Seidlein L, Luquero FJ, et al. The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans. The Lancet Infect Dis 2016; 16(1): 125-9.

  25. Djouma FN, Ateudjieu J, Ram M, et al. Factors Associated with Fatal Outcomes Following Cholera-Like Syndrome in Far North Region of Cameroon: A Community-Based Survey. Am J Trop Med Hyg 2016; doi:10.4269/ajtmh.16-0300.

  26. Federspiel, F., Ali, M. The cholera outbreak in Yemen: lessons learned and way forward. BMC Public Health 2018; 18:1338.

  27. Finger, Flavio, Bertuzzo, Enrico, Luquero, Francisco, et al. The potential impact of case-area targeted interventions in response to cholera outbreaks: A modeling study. PLoS Med 2018; 15(2): e1002509.

  28. Hall RH, Sack DA. Introducing cholera vaccination in Asia, Africa and Haiti: A meeting report. Vaccine 2015; 33(4): 487-92.

  29. Ivers LC, Hilaire IJ, Teng JE, et al. Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. The Lancet Glob Health 2015; 3(3): e162-8.

  30. Ivers LC, Teng JE, Lascher J, et al. Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 2013; 89(4): 617-24.

  31. Iyer AS, Bouhenia M, Rumunu J, et al. Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan. Sci Rep 2016; 6: 35742.

  32. Khan, A. I., Ali, M., Chowdhury, F., Saha, A., Khan, I. A., Khan, A., et al. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh. Vaccine 2017; 35(11): 1538-1543.

  33. Lopez AL, Macasaet LY, Ylade M, Tayag EA, Ali M. Epidemiology of cholera in the Philippines. PLoS Negl Trop Dis 2015; 9(1): e3440.

  34. Lopez AL, Deen J, Azman AS, Luquero FJ, Kanungo S, Dutta S, von Seidlein L, Sack DA. Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: A systematic review and metaanalysisClinical Infectious Diseases 2017; cix1039.

  35. Luquero FJ, Sack DA. Effectiveness of oral cholera vaccine in Haiti. The Lancet Glob Health 2015; 3(3): e120-1.

  36. Luquero FJ, Ballard A, Sack DA. Ensuring access to oral cholera vaccine to those who need them most. Vaccine 2017; 35(3): 411. 

  37. Martin S, Lopez AL, Bellos A, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bulletin of the World Health Organization 2014; 92(12): 881-93.

  38. M'bangome M, Pezzoli L, Reeder B, et al. Oral cholera vaccine in cholera prevention and control, Malawi. Bulletin of the World Health Organization 2018; 96(6): 428-435.

  39. Parker LA, Rumunu J, Jamet C, et al. Adapting to the global shortage of cholera vaccines: targeted single dose cholera vaccine in response to an outbreak in South Sudan. The Lancet Infectious Diseases 2017.

  40. Parker LA, Rumunu J, Jamet C, et al. Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage. PLoS Neglected Tropical Diseases 2017; 11(6): e0005652.

  41. Peak CM, Reilly AL, Azman AS, Buckee CO. Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects. PLoS Negl Trop Dis 2018. 12(2): e0006257.

  42. Qadri F, Wierzba TF, Ali M, et al. Efficacy of a Single-Dose, Inactivated Oral Cholera Vaccine in Bangladesh. N Engl J Med 2016; 374(18): 1723-32.

  43. Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. The Lancet 2015.

  44. Sack DA. A new era in the history of cholera: the road to elimination. Int J Epidemiol 2013; 42(6): 1537-40.

  45. Sack DA, Ali M. Protection from killed oral cholera vaccine continues for 4 years. The Lancet Global Health 2018; 6(9): PE946-E947.

  46. Troeger C, Sack DA, Chao DL. Evaluation of targeted mass cholera vaccination strategies in Bangladesh: a demonstration of a new cost-effectiveness calculator. Am J Trop Med Hyg 2014; 91(6): 1181-9.

  47. Von Seidlein, L, Sack, D, Azman, A, et al. Cholera outbreak in Yemen. The Lancet Gastroenterology & Hepatology 2017; 2(11): 777.

  48. Von Seidlein, Lorenz and Deen, Jacqueline. Preventing cholera outbreaks through early targeted interventions. PLoS Med 2018; 15(2): e1002510.

  49. Yakum MN, Ateudjieu J, Guenou E, Walter EA, et al. Health seeking behaviour among suspected cases of cholera in Cameroonian health districts in Lake Chad basin. BMC Res Notes 2017; 10(1): 433.